natgillin/translations-raw huggingface dataset:
b. Wipe your skin with an alcohol wipe. 
Obrišite kožu vatom natopljenom alkoholom.
Plegridy can be used during breastfeeding. 
Plegridy se može koristiti tijekom dojenja.
External heat sources such as hot water must not be used to warm Plegridy. 
Vanjski izvori topline poput vruće vode ne smiju se koristiti za zagrijavanje Plegridyja.
The pharmacological properties of Plegridy are consistent with those of interferon beta-1a and are believed to be mediated by the protein portion of the molecule. 
Farmakološka svojstva Plegridyja u skladu su s onima interferona beta-1a i vjeruje se da su posredovana proteinskim dijelom molekule.
Your doctor may want to check your blood pressure, blood (platelet count) and the function of your kidneys. 
Liječnik će Vam možda htjeti provjeriti krvni tlak, provesti krvne pretrage (broj trombocita) i provjeriti funkciju bubrega.
Step 2: Collect your supplies and wash your hands. 
2. korak: Prikupite pribor i operite ruke a.
This could lock the pen 
To bi moglo zaključati brizgalicu.
Pharmacokinetics observed in multiple sclerosis patients were consistent with those seen in healthy subjects. 
Farmakokinetika opažena u bolesnika s multiplom sklerozom bila je dosljedna farmakokinetici opaženoj kod zdravih ispitanika.
Step 11: Check your injection site 
11. korak: Pregledajte mjesto injekcije
1285 patients received at least 1 year, 1124 patients have received at least 2 years, 947 patients received at least 3 years, and 658 patients received at least 4 years of treatment with Plegridy. 
Od toga je 1285 bolesnika bilo liječeno Plegridyjem najmanje 1 godinu, 1124 bolesnika najmanje 2 godine, 947 bolesnika najmanje 3 godine, a 658 bolesnika najmanje 4 godine.
Data from patients treated up to 2 years with Plegridy suggests that less than 1% (5/715) developed persistent-neutralising antibodies to the interferon beta-1a portion of peginterferon beta-1a. 
Podaci bolesnika koji su liječeni do 2 godine Plegridyjem pokazuju da je manje od 1% (5/715) razvilo perzistentna neutralizirajuća protutijela na interferon beta-1a u peginterferonu beta-1a.
Patients should be advised to immediately report any symptoms of depression and/or suicidal ideation to their prescribing physician. 
Bolesnike je potrebno savjetovati da odmah prijave svom liječniku bilo koji simptom depresije i/ili suicidalnih ideacija.
Of the patients who reported flu-like symptoms 90% reported them as mild or moderate in severity. 
Od bolesnika koji su prijavili simptome nalik gripi, 90% ih je prijavilo kao simptome blage ili umjerene težine.
• Gently pinch the skin around the cleaned injection site using thumb and forefinger to create a slight bulge (See Figure G). 
• Nježno stisnite kožu oko očišćenog mjesta za injekciju koristeći palac i kažiprst tako da se odigne u nabor (pogledajte sliku G).
• After the needle is in, let go of your skin. 
• Nakon uvođenja igle u nabor možete otpustiti kožu.
• Plegridy pre-filled syringe should be injected into the abdomen, thigh, or the back of the upper arm. (See Figure E). 
• Plegridy u napunjenoj štrcaljki treba ubrizgati u trbuh, natkoljenicu ili stražnju stranu nadlaktice (pogledajte sliku E).
Do not inject into an area of your body where the skin is irritated, red, bruised, tattooed, infected, or scarred. 
Nemojte ubrizgati lijek u područje tijela gdje je koža nadražena, osjetljiva, crvena, inficirana ili prekrivena modricama, tetovažama ili ožiljcima.
Plegridy is for subcutaneous use. 
Plegridy je namijenjen za supkutanu primjenu.
- For patients with ≥2 relapses in the previous year and at least 1 Gd+ lesion (n=273), the annual relapse rate at 1 year was 0.47 for placebo, 0.35 for Plegridy every 4 weeks, and 0.33 for Plegridy every 2 weeks. 
- Za bolesnike s ≥2 relapsa u prethodnoj godini i najmanje 1 Gd+ lezijom (n=273), godišnja je stopa relapsa nakon 1 godine bila 0,47 za placebo, 0,35 za Plegridy svaka 4 tjedna i 0,33 za Plegridy svaka 2 tjedna.
• Keep Plegridy pen and all medicines out of reach of children. 
• Čuvajte brizgalicu Plegridy i sve lijekove izvan dohvata djece.
Day 14 (94 micrograms) 
14. dan (94 mikrograma)
In both patients, cell counts recovered after discontinuation of Plegridy. 
U oba bolesnika, broj stanica se oporavio nakon prekida liječenja Plegridyjem.
• Slowly push the plunger all the way down until syringe is empty (See Figure I). 
• Polagano pritišćite klip sve do kraja dok se štrcaljka ne isprazni (pogledajte sliku I).
Urinary (renal) clearance is postulated to be a major excretory pathway for Plegridy. 
Pretpostavlja se da je urinarni (renalni) klirens glavni put izlučivanja Plegridyja.
Choose the correct syringe from a pack. 
Odaberite ispravnu štrcaljku iz pakiranja.
• Remove one Plegridy pack out of the fridge and select the appropriate pre-filled syringe from the pack. 
• Izvadite iz hladnjaka jedno pakiranje Plegridyja i odaberite odgovarajuću napunjenu štrcaljku iz pakiranja.
However, the development of antibodies against the interferon moiety of peginterferon beta-1a had no discernible impact on safety or clinical efficacy, although the analysis was limited by the low immunogenicity incidence. 
Međutim, razvoj protutijela protiv interferona u peginterferonu beta-1a nije imao zamjetan učinak na sigurnost i kliničku djelotvornost, iako je analiza bila ograničena niskom incidencijom imunogenosti.
Use the record table printed on the inside of the lid of the Initiation Pack to keep a track of your injection dates. 
Koristite tablicu za bilježenje koja je otisnuta na unutarnjem dijelu poklopca pakiranja za početak liječenja kako biste vodili evidenciju o datumima davanja injekcija.
• Each Plegridy pre-filled syringe can be used once only. 
• Jedna napunjena štrcaljka Plegridyja smije se upotrijebiti samo jedanput.
Three percent of patients (18/681) developed persistent antibodies to the PEG moiety of peginterferon beta-1a. 
U 3% bolesnika (18/681) razvila su se perzistentna protutijela na PEG skupinu u peginterferonu beta-1a.
• Check with your doctor, pharmacist or nurse about the right way to throw away the used syringe. 
• Provjerite s liječnikom, ljekarnikom ili medicinskom sestrom kako na ispravan način baciti upotrijebljenu štrcaljku.
• Using one hand, hold the syringe by the glass barrel. 
• Jednom rukom držite štrcaljku za stakleno tijelo.
The duration of this response was sustained and prolonged for Plegridy, with elevations detected up to 15 days compared to 4 days for non-pegylated interferon beta-1a. 
Trajanje tog odgovora bilo je održano i produljeno za Plegridy, s povišenjima detektiranim do 15 dana u odnosu na 4 dana za nepegilirani interferon beta-1a.
Thrombotic microangiopathy (TMA) (class effects) 
Trombotička mikroangiopatija (TMA) (učinak skupine lijekova)
Two serious cases were reported in patients treated with Plegridy: one patient (<1%) experienced severe thrombocytopenia (platelet count <10 x 109/L), another patient (<1%) experienced severe neutropenia (neutrophil count <0.5 x 109/L). 
Dva ozbiljna slučaja zabilježena su u bolesnika liječenih Plegridyjem: jedan bolesnik (<1%) doživio je tešku trombocitopeniju (broj trombocita <10 x 109/l), a drugi bolesnik (<1%) razvio je tešku neutropeniju (broj neutrofila <0,5 x 109/l).
Decreases in white blood cell counts of <3.0 x 109/L were observed in 7% of patients receiving Plegridy and in 1% receiving placebo. 
Smanjenja broja bijelih krvnih stanica od <3,0 x 109/l opažena su u 7% bolesnika koji su primali Plegridy i u 1% koji su primali placebo.
Plegridy pre-filled pen must not be used unless the green stripes are visible in the pen injection status window. 
Plegridy u napunjenoj brizgalici ne smije se koristiti ako zelene trake nisu vidljive u prozorčiću statusa injekcije u napunjenoj brizgalici.
Plegridy every 2 weeks significantly reduced the annualized relapse rate (ARR) by 36% compared to placebo (p=0.0007) at one year (Table 3) with consistent reductions of the ARR noted in subgroups defined by demographic and baseline disease characteristics. 
Plegridy davan svaka 2 tjedna značajno je smanjio godišnju stopu relapsa (ARR) za 36% u odnosu na placebo (p = 0,0007) nakon jedne godine (tablica 3), s dosljednim smanjenjima ARR opaženima u podskupinama definiranim demografskim obilježjima i obilježjima bolesti na početku ispitivanja.
Cardiac disease 
Bolesti srca
The available information on the effects of interferon beta-1a in the peri- and postnatal periods is limited. 
Dostupni podaci o učincima interferona beta-1a u pre i postnatalnom razdoblju su ograničeni.
Treatment initiation 
Započinjanje liječenja
Very common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1/1, 000 to <1/100) Rare (≥1/10, 000 to <1/1,000) 
Učestalost nuspojava u nastavku razvrstana je prema sljedećim kategorijama: vrlo često (≥1/10) često (≥1/100 i <1/10) manje često (≥1/1000 i <1/100) rijetko (≥1/10 000 i <1/1000) vrlo rijetko (<1/10 000) nepoznato (ne može se procijeniti iz dostupnih podataka)
Laboratory abnormalities are associated with the use of interferons. 
Abnormalnosti u laboratorijskim nalazima povezane su s primjenom interferona.
• After 2 hours, check the injection site for redness, swelling, or tenderness. 
• Nakon 2 sata provjerite je li mjesto injekcije crveno, otečeno, ili osjetljivo.
Each haemodialysis reduced peginterferon beta-1a concentration by approximately 24%, suggesting that haemodialysis partially removes peginterferon beta-1a from systemic circulation. 
Jedna hemodijaliza smanjuje koncentraciju peginterferona beta-1a za oko 24%, što ukazuje na to da hemodijaliza djelomično uklanja peginterferon beta-1a iz sistemske cirkulacije.
The most common adverse drug reactions (ADR) (at a higher incidence than placebo) for Plegridy 125 micrograms subcutaneously every 2 weeks were injection site erythema, influenza like illness, pyrexia, headache, myalgia, chills, injection site pain, asthenia, injection site pruritus, and arthralgia. 
Najčešće nuspojave (veća incidencija nego placebo) Plegridyja u dozi od 125 mikrograma supkutanom injekcijom svaka 2 tjedna bile su eritem na mjestu injiciranja, bolest nalik gripi, pireksija, glavobolja, mialgija, zimica, bol na mjestu injiciranja, astenija, pruritus na mjestu injiciranja i artralgija.
c. Continue to hold the pen firmly down on your injection site until the clicking sounds have stopped (see Figure H). 
Nastavite čvrsto držati brizgalicu pritisnutu na mjesto injekcije sve dok ne prestane zvuk otkucavanja (pogledajte sliku H).
Subcutaneous peginterferon beta-1a resulted in approximately 4-, 9-, and 13-fold higher exposure (AUC168h) values and approximately 2-, 3.5- and 5-fold higher Cmax, following single doses of 63 (6 MIU), 125 (12 MIU), and 188 (18 MIU) micrograms respectively, compared to intramuscular administration of 30 (6 MIU) micrograms non-pegylated beta-1a. 
Supkutano injiciranje peginterferona beta-1a rezultiralo je otprilike u 4, 9, i 13 puta višim vrijednostima izloženosti (AUC168h) i u otprilike 2, 3,5 i 5 puta višim Cmax, nakon primjene jednokratne doze od 63 (6 MIU), 125 (12 MIU), odnosno 188 (18 MIU) mikrograma u usporedbi s intramuskularnim primjenom od 30 (6 MIU) mikrograma nepegiliranog interferona beta-1a.
One patient out of 1468 patients who received Plegridy in clinical studies experienced an injection site necrosis which resolved with standard medical treatment. 
Jedan bolesnik od 1468 bolesnika koji su primali Plegridy u kliničkim ispitivanjima razvio je nekrozu na mjestu injiciranja što je uklonjeno standardnim liječenjem.
A treatment effect was observed as early as 6 months, with Plegridy 125 micrograms every 2 weeks demonstrating a 61% reduction (p<0.0001) in new or newly enlarging T2 lesions as compared with placebo. 
Učinak liječenja uočen je već nakon 6 mjeseci, pri čemu je primjena 125 mikrograma Plegridyja svaka dva tjedna pokazala smanjenje od 61% (p<0,0001) novih ili novo povećanih T2 lezija u usporedbi s placebom.
Preparing for your injection Step 1: Remove your pen from the fridge. 
Priprema za injekciju 1. korak: Izvadite brizgalicu iz hladnjaka a.
If you forget to use Plegridy 
Ako ste zaboravili primijeniti Plegridy
Treatment should be initiated under supervision of a physician experienced in the treatment of multiple sclerosis. 
4.2 Doziranje i način primjene Liječenje treba započeti pod nadzorom liječnika koji ima iskustva u liječenju multiple skleroze.
Table 1: Titration schedule at initiation Dose 
Raspored titracije kod započinjanja
Proportion with 24-week confirmed disability progression* 
Udio s potvrđenom progresijom onesposobljenosti u 24. tjednu* HR
An open-label study in patients switching from interferon beta therapy to Plegridy evaluated the onset and duration of prophylactically treated flu-like symptoms. 
U otvorenom ispitivanju provedenom u bolesnika koji su prebačeni s terapije interferonom beta na Plegridy procijenjeni su početak i trajanje profilaktički liječenih simptoma nalik gripi.
• Let the injection site dry before injecting the dose. 
• Pustite da se mjesto za injekciju osuši prije ubrizavanja doze.
The incidence of potentially clinically significant decreases in RBC counts (<3.3 x 1012/L) was similar in Plegridy-treated patients compared to placebo-treated patients. 
Incidencija potencijalno klinički značajnog smanjenja broja crvenih krvnih stanica (<3,3 x 1012/l) bila je slična u bolesnika liječenih Plegridyjem u usporedbi s bolesnicima koji su dobivali placebo.
Patients should be advised to rotate sites for subcutaneous injections. 
Bolesnike treba savjetovati da mijenjaju mjesta davanja supkutanih injekcija.
Pharmacotherapeutic group: Antineoplastic and immunomodulating agents, immunostimulants, interferons, ATC code: L03AB13 
Farmakoterapijska skupina: Antineoplastici i imunomodulatori, imunostimulansi, interferoni,
Laboratory findings suggestive of TMA include decreased platelet counts, increased serum lactate dehydrogenase (LDH) due to haemolysis and schistocytes (erythrocyte fragmentation) on a blood film. 
Laboratorijski nalazi koji upućuju na TMA, uključuju smanjen broj trombocita, povećanu razinu laktat dehidrogenaze (LDH) u serumu zbog hemolize i shistocite (fragmentirani eritrociti) u krvnom razmazu.
Plegridy should be administered with caution to patients with previous depressive disorders (see section 4.3). 
Plegridy treba primjenjivati s oprezom kod bolesnika s prethodnim depresivnim poremećajima (vidjeti dio 4.3).
Depression occurs with increased frequency in the multiple sclerosis population and in association with interferon use. 
U populaciji s multiplom sklerozom depresija se javlja s povećanom učestalosti i povezana je s primjenom interferona.
- If you are unsure of the number of days you have kept a syringe out of the fridge, throw the syringe away. 
Ako niste sigurni koliko je dugo štrcaljka bila izvan hladnjaka, tada bacite tu štrcaljku.
A pre-filled syringe of Plegridy is contained within a single-use, disposable, spring-powered pen injector called Plegridy Pen. 
Napunjena štrcaljka Plegridyja nalazi se unutar brizgalice za jednokratnu uporabu s oprugom, nazvane Plegridy Pen.
The usual sites for subcutaneous injections include abdomen, arm, and thigh. 
Uobičajena mjesta davanja supkutanih injekcija su trbuh, nadlaktice i bedra.
Cessation of therapy with Plegridy should be considered (see section 4.8). 
Treba razmotriti odluku o prekidu liječenja Plegridyjem (vidjeti dio 4.8).
Following subcutaneous administration of peginterferon beta-1a in multiple sclerosis patients, the peak concentration was reached between 1 to 1.5 days post-dose. 
Nakon supkutane primjene peginterferona beta-1a u bolesnika s multiplom sklerozom, vršna koncentracija postignuta je između 1 do 1,5 dana nakon primjene doze.
Orange 
Narančasta
Table 2: Study design 
Tablica 2. Ustroj ispitivanja
Caution should be exercised when Plegridy is administered in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance, e.g. some classes of antiepileptics and antidepressants. 
Plegridy treba davati s osobitom pozornošću u kombinaciji s lijekovima koji imaju uzak terapijski indeks i čiji je klirens vrlo ovisan o sustavu jetrenog P450 citokroma, primjerice s nekim skupinama antiepileptika i antidepresiva.
Plegridy is to be injected under the skin (subcutaneous injection). 
Plegridy se ubrizgava pod kožu (potkožna injekcija).
Increased concentrations of neopterin were observed in both healthy subjects and multiple sclerosis patients treated with Plegridy, with a sustained and prolonged elevation over 10 days compared to 5 days observed for non-pegylated interferon beta-1a. 
Povećane koncentracije neopterina zabilježene su i u zdravih ispitanika i u bolesnika s multiplom sklerozom liječenih Plegridyjem, s održanim i produljenim povišenjem tijekom 10 dana u odnosu na 5 dana za nepegilirani interferon beta-1a.
A definitive mechanism of action of peginterferon beta-1a in multiple sclerosis (MS) is not known. 
Mehanizam djelovanja Točan mehanizam djelovanja peginterferona beta-1a u multiploj sklerozi (MS) nije poznat.
In multiple sclerosis patients, the t1/2 (mean±SE) of peginterferon beta-1a was 78 ± 15 hours at steady state. 
U bolesnika s multiplom sklerozom, t1/2 (srednja vrijednost ± SE) peginterferona beta-1a bio je 78 ± 15 sati u stanju dinamičke ravnoteže.
Early clinical features include thrombocytopenia, new onset hypertension, fever, central nervous system symptoms (e.g. confusion, paresis) and impaired renal function. 
Rane kliničke značajke uključuju trombocitopeniju, novonastalu hipertenziju, vrućicu, simptome središnjeg živčanog sustava (npr. konfuzija, pareza) i oštećenje bubrežne funkcije.
Upon repeated dosing with peginterferon beta-1a of sexually mature female monkeys, effects on menstrual cycle length and progesterone levels were observed. 
Nakon ponovljenog doziranja peginterferona beta-1a spolno zrelim ženkama majmuna, zabilježeni su učinci na duljinu trajanja menstrualnog ciklusa i razine progesterona.
What Plegridy is and what it is used for 
Što je Plegridy i za što se koristi
Day 0 (63 micrograms) 
0. dan (63 mikrograma)
After that you will be provided with a maintenance pack containing grey syringes with Plegridy 125 micrograms (for day 28 and then every two weeks). 
Nakon toga ćete dobiti pakiranje za održavanje liječenja koje sadrži sive štrcaljke s Plegridyjem od 125 mikrograma (za 28. dan te nakon toga svaka dva tjedna).
Do not use external heat sources, such as hot water, to warm your pen. 
Nemojte koristiti vanjske izvore topline poput vruće vode kako biste zagrijali brizgalicu.
Influenza like illness 
Simptomi nalik gripi
See below for simple ways to manage these flu-like symptoms if you get them. 
Ako dobijete te simptome pogledajte dolje opis jednostavnih načina za kontroliranje tih simptoma nalik gripi.
Repeated dose toxicology studies were limited to 5 weeks as exposure was greatly diminished from 3 weeks onwards, due to the formation of anti-drug antibodies by rhesus monkeys to human interferon beta-1a. 
Ispitivanja toksičnosti ponovljenih doza bila su ograničena na 5 tjedana, jer je izloženost bila znatno smanjena od 3. tjedna nadalje zbog stvaranja protutijela protiv lijeka na ljudski interferon beta-1a u rezus majmuna.
The most commonly reported adverse reaction leading to discontinuation in patients treated with Plegridy 125 micrograms subcutaneously every 2 weeks was influenza-like illness (<1%). 
Najčešće prijavljena nuspojava koja je dovela do prekida liječenja u bolesnika liječenih Plegridyjem u dozi od 125 mikrograma supkutanom injekcijom svaka 2 tjedna, bila je bolest nalik gripi (<1%).
Solution for injection Multipack: 6 (3 packs of 2) pre-filled pens of 125 micrograms. 
Otopina za injekciju Višestruko pakiranje: 6 (3 pakiranja od 2) napunjenih brizgalica od 125 mikrograma.
The liquid in the medicinal product window must be clear and colourless. 
Tekućina u prozorčiću za prikaz lijeka mora biti bistra i bezbojna.
(may affect more than 1 in 10 people) - Flu-like symptoms. 
Vrlo česte nuspojave (mogu se pojaviti u više od 1 na 10 osoba) - simptomi nalik gripi.
Direct comparative data for Plegridy versus non-pegylated interferon beta or data on efficacy of Plegridy after switching from a non-pegylated interferon beta are not available. 
Nisu dostupni izravni usporedni podaci za Plegridy naspram nepegiliranog interferona beta ili podaci o djelotvornosti Plegridyja nakon prebacivanja s nepegiliranog interferona beta.
• If some areas are too difficult for you to reach, ask a carer who has been trained to help you. 
• Ako Vam je teško dosegnuti neka područja, zamolite uvježbanog njegovatelja da Vam pomogne.
- Do not use this medicine if you notice any of the following: - If the syringe is broken. 
Nemojte primijeniti ovaj lijek ako primijetite bilo što od sljedećeg:
Step 9: Dispose of used Plegridy pen 
9. korak: Odlaganje upotrijebljene štrcaljke Plegridyja
Step 8: Remove the pre-filled syringe from your injection site 
8. korak: Izvucite štrcaljku s mjesta injekcije
- Throw away any syringe that is kept out of the fridge for more than 30 days. 
- Bacite štrcaljku koja je bila izvan hladnjaka više od 30 dana.
Do not inject directly into your belly button. 
Nemojte ubrizgati lijek izravno u pupak.
Do not use Plegridy pre-filled syringe past the expiry date. 
Nemojte koristiti napunjenu štrcaljku Plegridyja nakon datuma isteka roka valjanosti.
Elevations in hepatic enzymes have been observed with the use of Plegridy. 
Uočena su povišenja jetrenih enzima tijekom liječenja Plegridyjem.
What Plegridy is 
Što je Plegridy
Do not share the pen with anyone else to avoid giving an infection to them or getting an infection from them. 
Nemojte ni s kim dijeliti svoju brizgalicu kako ne biste prenijeli ili dobili neku infekciju.
The table summarizes ADRs (incidence above placebo and with a reasonable possibility of causality) from 512 patients treated with Plegridy 125 micrograms subcutaneously every 2 weeks and 500 patients who received placebo for up to 48 weeks and post-marketing data. 
Tablica sažeto prikazuje nuspojave (incidencija veća od placeba i opravdana mogućnost uzročne povezanosti) kod 512 bolesnika liječenih Plegridyjem od 125 mikrograma supkutano svaka 2 tjedna, i 500 bolesnika koji su primali placebo do 48 tjedana, te iz podataka nakon stavljanja lijeka u promet.
Plegridy contains sodium 
Plegridy sadrži natrij
If you get some or all of these symptoms: Increased bruising or bleeding Extreme weakness 
Ako Vam se pojave neki ili svi sljedeći simptomi: - povećano stvaranje modrica ili povećano krvarenje
(frequency cannot be estimated from the available data) - Pulmonary arterial hypertension: A disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels that carry blood from the heart to the lungs. 
Nepoznata učestalost (nepoznata učestalost - učestalost se ne može procijeniti na temelju dostupnih podataka) - plućna arterijska hipertenzija: bolest jakog suženja krvnih žila u plućima što rezultira visokim krvnim tlakom u krvnim žilama koje prenose krv iz srca u pluća.
One patient treated with Plegridy in clinical trials experienced an injection site necrosis. 
Jedan bolesnik liječen Plegridyjem u kliničkom ispitivanju razvio je nekrozu na mjestu injiciranja.
Take paracetamol or ibuprofen half an hour before your Plegridy injection and continue to take paracetamol or ibuprofen for the duration of your flu-like symptoms. 
Nastavite uzimati paracetamol ili ibuprofen sve dok Vam traju simptomi nalik gripi.
Decreased peripheral blood counts in all cell lines, including rare pancytopenia and severe thrombocytopenia, have been reported in patients receiving interferon beta. 
Smanjenje broja perifernih krvnih stanica u svim linijama stanica, uključujući i rijetku pancitopeniju i tešku trombocitopeniju, zabilježeno je u bolesnika koji su primali interferon beta.
Before use - Parts of Plegridy Pen (Figure A) 
Prije upotrebe - dijelovi brizgalice Plegridy (Slika A)